GT
PHAS

Glenmede Trust’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Glenmede Trust’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,000
Closed -$20 – 3164
2019
Q3 		$20 Hold
5,000
– – ﹤0.01% 2049
2019
Q2 		$65 Buy
+5,000
New +$61.3K ﹤0.01% 1557

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Glenmede Trust's PHAS Position: Q4 2019 in Review

Glenmede Trust sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2019, closing a stake of 5,000 shares — an estimated $20 sold.

Glenmede Trust first reported a position in PHAS in Q2 2019 and held it in 2 quarters. The position peaked at $65 in Q2 2019. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2019.

  • Glenmede Trust reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Glenmede Trust sold 5,000 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $20.
  • Glenmede Trust first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Glenmede Trust's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $65 in Q2 2019.
  • 51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.